{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:27:36Z","timestamp":1794000456348,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tmrv.2026.151040","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:10:32Z","timestamp":1789085432000},"page":"151040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Testosterone-Associated Erythrocytosis and Blood Donation: Therapeutic Phlebotomy, Donor Safety, and Recipient Exposure"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9106-1858","authenticated-orcid":false,"given":"Emilya","family":"Huseynova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2715-642X","authenticated-orcid":false,"given":"Waseem","family":"Anani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2026.151040_bib0001","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.juro.2016.10.063","article-title":"Trends in testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States","volume":"197","author":"Rao","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.tmrv.2026.151040_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309160","article-title":"Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018-2022","volume":"19","author":"Selinger","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2026.151040_bib0003","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/bloodadvances.2024015410","article-title":"Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review","volume":"9","author":"Liu","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2026.151040_bib0004","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/trf.15754","article-title":"The prevalence and demographic determinants of blood donors receiving testosterone replacement therapy at a large USA blood service organization","volume":"60","author":"Hazegh","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151040_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ajcp\/aqaa019","article-title":"Therapeutic phlebotomy for testosterone-induced polycythemia","volume":"154","author":"Van Buren","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.tmrv.2026.151040_bib0006","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0283","article-title":"Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?","volume":"13","author":"Bond","year":"2024","journal-title":"Endocr Connect"},{"key":"10.1016\/j.tmrv.2026.151040_bib0007","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.icheatmasstransfer.2014.07.024","article-title":"New method of hematocrit correction of whole blood viscosity","volume":"57","author":"Cho","year":"2014","journal-title":"Intl Commun Heat Mass Transfer"},{"key":"10.1016\/j.tmrv.2026.151040_bib0008","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4149\/gpb_2014009","article-title":"Determination of whole blood and plasma viscosity by means of flow curve analysis","volume":"33","author":"Ruef","year":"2014","journal-title":"Gen Physiol Biophys"},{"key":"10.1016\/j.tmrv.2026.151040_bib0009","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/JU.0000000000002437","article-title":"Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy","volume":"207","author":"Ory","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.tmrv.2026.151040_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/JU.0000000000002791","article-title":"Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy. Reply","volume":"208","author":"Ory","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.tmrv.2026.151040_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/HP.S54455","article-title":"The role of PHD2 mutations in the pathogenesis of erythrocytosis","volume":"2","author":"Gardie","year":"2014","journal-title":"Hypoxia (Auckl)"},{"key":"10.1016\/j.tmrv.2026.151040_bib0012","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tmrv.2026.151040_bib0013","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/andr.12770","article-title":"European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European Society of Endocrinology","volume":"8","author":"Corona","year":"2020","journal-title":"Andrology"},{"key":"10.1016\/j.tmrv.2026.151040_bib0014","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5534\/wjmh.221027","article-title":"The British Society for Sexual Medicine Guidelines on male adult testosterone deficiency, with statements for practice","volume":"41","author":"Hackett","year":"2023","journal-title":"World J Mens Health"},{"key":"10.1016\/j.tmrv.2026.151040_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5694\/mja16.00448","article-title":"Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations","volume":"205","author":"Yeap","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.tmrv.2026.151040_bib0016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cen.14633","article-title":"Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism","volume":"96","author":"Jayasena","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.tmrv.2026.151040_bib0017","unstructured":"U.S. Food and Drug Administration. Guidance for industry: variances for blood collection from individuals with hereditary hemochromatosis. 2001. https:\/\/www.federalregister.gov\/documents\/2001\/08\/23\/01-21247\/guidance-for-industry-variances-for-blood-collection-from-individuals-with-hereditary."},{"key":"10.1016\/j.tmrv.2026.151040_bib0018","series-title":"Requirements for blood and blood components intended for transfusion or for further manufacturing use; final rule","first-page":"29842","year":"2015"},{"key":"10.1016\/j.tmrv.2026.151040_bib0019","unstructured":"U.S. Food and Drug Administration. Exceptions and alternative procedures approved under 21 CFR 640.120. 2018. https:\/\/www.fda.gov\/media\/111933\/download (Accessed: August 17, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0020","unstructured":"Association for the Advancement of Blood & Biotherapies. Ask the FDA and CLIA: 2014 transcript. 2014. https:\/\/www.aabb.org\/regulatory-and-advocacy\/regulatory-affairs\/resources\/ask-the-fda-and-clia-transcripts\/2014-ask-the-fda-and-clia-transcript (Accessed: April 14, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0021","unstructured":"Association for the Advancement of Blood & Biotherapies. Ask the FDA and CLIA: 2018 transcript. 2018. https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/regulatory\/2018-ask-the-fda-and-clia-transcript.pdf (Accessed: April 14, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0022","unstructured":"Association for the Advancement of Blood & Biotherapies. Ask the FDA and CLIA: 2025 transcript. 2025. https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/regulatory\/2025-ask-the-fda-and-clia-transcript.pdf (Accessed: April 14, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0023","unstructured":"U.S. Food and Drug Administration. 21 CFR \u00a7 630.15\u2014Donor eligibility requirements specific to whole blood and red blood cells. https:\/\/www.ecfr.gov\/current\/title-21\/part-630."},{"key":"10.1016\/j.tmrv.2026.151040_bib0024","unstructured":"Joint Professional Advisory Committee to the UK Blood Transfusion and Transplantation Services. Testosterone replacement therapy. WB-DSG edition 203 release 79. 2026. https:\/\/www.jpac.org.uk\/guidelines\/wb\/index\/testosterone-replacement-therapy\/(Accessed: August 20, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0025","unstructured":"ARC Lifeblood. High ferritin FAQs. 2026. https:\/\/www.lifeblood.com.au\/health-professionals\/clinical-practice\/clinical-indications\/high-ferritin (Accessed: August 20, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0026","unstructured":"Canadian Blood Services. Eligibility: hemoglobin and iron. 2026. https:\/\/www.blood.ca\/en\/blood\/am-i-eligible-donate-blood\/eligibility\/hemoglobin-iron (Accessed: August 20, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0027","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/gerona\/glt154","article-title":"Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point","volume":"69","author":"Bachman","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.tmrv.2026.151040_bib0028","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jc.2018-01702","article-title":"Risk of erythrocytosis during concomitant testosterone and SGLT2-inhibitor treatment: a warning from two clinical cases","volume":"104","author":"Motta","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tmrv.2026.151040_bib0029","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/clinem\/dgab089","article-title":"Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years","volume":"106","author":"Madsen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tmrv.2026.151040_bib0030","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tmrv.2026.151040_bib0031","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1111\/trf.16658","article-title":"Toxic masculinity in red blood cell units? Testosterone therapy in blood donors revisited","volume":"61","author":"Hazegh","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151040_bib0032","doi-asserted-by":"crossref","DOI":"10.1111\/trf.18149","article-title":"Elevated plasma testosterone concentrations from males on testosterone replacement therapy are mitigated with pathogen reduction technology","author":"Greenwall","year":"2025","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151040_bib0033","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/jcem-36-6-1132","article-title":"Total and unbound testosterone levels in the newborn and in normal and hypogonadal children: use of a sensitive radioimmunoassay for testosterone","volume":"36","author":"Forest","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tmrv.2026.151040_bib0034","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/trf.18485","article-title":"Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components","volume":"66","author":"Greenwall","year":"2026","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151040_bib0035","unstructured":"Regulation (EU) 2024\/1938 of the European Parliament and of the Council of 13 June 2024 on standards of quality and safety for substances of human origin intended for human application and repealing directives 2002\/98\/EC and 2004\/23\/EC) Document 32024R1938. Available at: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=OJ:L_202401938."},{"key":"10.1016\/j.tmrv.2026.151040_bib0036","unstructured":"U.S. Food and Drug Administration. Information for consumers on using dietary supplements. https:\/\/www.fda.gov\/food\/dietary-supplements\/information-consumers-using-dietary-supplements. 2022. (Accessed: May 22, 2026)."},{"key":"10.1016\/j.tmrv.2026.151040_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3337","article-title":"Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings","volume":"1","author":"Tucker","year":"2018","journal-title":"JAMA Netw Open"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796326000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796326000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:00:55Z","timestamp":1793998855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796326000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S0887796326000817"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2026.151040","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone-Associated Erythrocytosis and Blood Donation: Therapeutic Phlebotomy, Donor Safety, and Recipient Exposure","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2026.151040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151040"}}